Skip to content
Catalyst

PapersPMID:36074799

The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial.

Journal of integrative and complementary medicine2022The record ↗

  1. Finding, very limited evidenceno difference foundHepatic fat fraction by MRI-PDFF

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “The authors found a reduction in MRI-PDFF between weeks 0 and 24 in the oligonol group; however, the change was not different from the placebo group.”
    Study
    RCT
    Duration
    6 months
    Population
    Adults with non-alcoholic fatty liver disease (MRI-PDFF 11% or more)

Study record

Design
randomised controlled trial
Species
human
Population
Adult patients with NAFLD defined by MRI-PDFF of 11% or more; Oligonol, an oligomerized-polyphenol from Litchi chinensis extract (abstract only)
Participants
40
Comparator
placebo
Duration
168 days
Endpoints measured
4